Abstract:
:Advances in therapies have led to the approval of six therapeutic agents since 2004, each demonstrating overall survival benefit in randomized studies, and these have significantly improved the outlook for men facing metastatic castration-resistant prostate cancer (CRPC). More recently, efforts have been directed at trying to effect change at earlier phases of the disease. Apalutamide (ARN-509), a second-generation androgen receptor antagonist, recently received approval in the nonmetastatic (M0) CRPC space. Similar to enzalutamide, apalutamide inhibits the binding of androgen to androgen receptor (AR), nuclear translocation of the androgen-AR complex, and binding of AR transcription complex to DNA-binding sites and transcription elements. Phase I and II trial experience demonstrates the safety and tolerability of apalutamide, as well as its efficacy in effecting prostate-specific antigen response and radiographic-free survival in CRPC. US Food and Drug Administration approval in M0 CRPC was granted following positive results from the phase III SPARTAN study, where apalutamide demonstrated significant improvements in metastasis-free survival and time to symptomatic progression as compared to placebo.
journal_name
Onco Targets Therjournal_title
OncoTargets and therapyauthors
Chong JT,Oh WK,Liaw BCdoi
10.2147/OTT.S147168subject
Has Abstractpub_date
2018-04-12 00:00:00pages
2141-2147issn
1178-6930pii
ott-11-2141journal_volume
11pub_type
杂志文章,评审abstract::Follicular dendritic cell sarcoma (FDCS) is a rare malignant tumor recognized in recent years. It accounts for only 0.4% of soft-tissue sarcomas, and its underlying causes are largely unknown. A correct diagnosis can be difficult to make. Diagnosis of FDCS depends on the combined clinical examination, histopathologic ...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S86502
更新日期:2015-07-24 00:00:00
abstract::Esophageal squamous cell carcinoma (ESCC) is often diagnosed at late incurable stage and lacks effective treatment strategy. Bufadienolides are cardiotonic steroids isolated from the skin and parotid venom glands of the toad Bufo bufo gargarizans Cantor with novel anticancer activity. However, there is little informat...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S104767
更新日期:2017-02-28 00:00:00
abstract:PURPOSE:Liver metastasis is one of the leading causes of death in colorectal cancer (CRC) patients. The present study aimed to evaluate the value of eIF4E as a prognostic marker of colorectal liver metastasis (CLM) and identify the functional role of eIF4E in CRC metastasis. PATIENTS AND METHODS:The expression level o...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S98330
更新日期:2016-02-19 00:00:00
abstract:Purpose:Sorafenib has revolutionized treatment of hepatocellular carcinoma (HCC), but its efficacy is limited by drug resistance. Autophagy is the process by which cellular components are transported to lysosomes for degradation, which promotes energy production and production of macromolecular precursors. Studies have...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S247655
更新日期:2020-04-28 00:00:00
abstract:Background/Aims:The effects of lncRNA-NORAD/mir-520a-3p on proliferation and invasion of non-small cell lung cancer (NSCLC) were studied, and its potential molecular mechanism was discussed. Methods:qRT-PCR was used to detect the expression of lncRNA NORAD and miR-520a-3p in non-small cell lung cancer tissues and cell...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S230954
更新日期:2020-02-19 00:00:00
abstract::Recently, "ipilimumab," an anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) monoclonal antibody, has been demonstrated to improve overall survival in metastatic melanoma. "CTLA-4" is an immune-checkpoint molecule that downregulates pathways of T-cell activation. Ipilimumab, by targeting CTLA-4, is able to remove the CTL...
journal_title:OncoTargets and therapy
pub_type: 杂志文章,评审
doi:10.2147/OTT.S57335
更新日期:2014-02-19 00:00:00
abstract::Triple-negative breast cancer is associated with a poor prognosis, and effective biomarkers for targeted diagnosis and treatment are lacking. The tumorigenicity of the provirus integration site for Moloney murine leukemia virus 1 (PIM-1) gene has been studied for many years. However, its significance in breast cancer ...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S212752
更新日期:2019-08-08 00:00:00
abstract:BACKGROUND:Progression-free survival (PFS) and time to progression (TTP) are frequently used to establish the clinical efficacy of anti-cancer drugs. However, the surrogacy of PFS/TTP for overall survival (OS) remains a matter of uncertainty in metastatic breast cancer (mBC). This study assessed the relationship betwee...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S63302
更新日期:2014-06-18 00:00:00
abstract::Intracranial myeloid sarcoma is a very rare disease with poor prognosis. We report a case of a 28-year-old male patient who was admitted with intense headache, vision disturbance and severe vomiting in June 2017. He had a history of neurosurgical tumor resection operation in April 2017, and the pathological diagnosis ...
journal_title:OncoTargets and therapy
pub_type:
doi:10.2147/OTT.S230478
更新日期:2020-01-09 00:00:00
abstract:BACKGROUND:The purpose of this study was to evaluate clinical outcomes of conventional fractionated helical tomotherapy in patients with small to medium hepatocellular carcinomas (HCCs) without portal vein tumor thrombosis. METHODS:Patients with up to four HCC lesions not treatable by surgery or percutaneous ablative ...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S69618
更新日期:2014-09-26 00:00:00
abstract:BACKGROUND:Tumor cells before and after epidermal growth-factor receptor (EGFR) tyrosine-kinase inhibitor (TKI) therapy might display different characteristics. The aim of this study was to evaluate the influence of prior EGFR TKI therapy on the efficacy of subsequent pemetrexed plus platinum (PP) in advanced chemonaïv...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S62639
更新日期:2014-05-23 00:00:00
abstract:Background:Erdheim-Chester Disease (ECD) is a clonal non-Langerhans histiocytosis, classified as a macrophage-dendritic cell neoplasm in the 2016 WHO classification. The exact cell of origin of ECD is unknown, although some limited evidence suggests that it arises from myeloid progenitors. Case Presentation:A 43-year-...
journal_title:OncoTargets and therapy
pub_type:
doi:10.2147/OTT.S276497
更新日期:2020-11-16 00:00:00
abstract::Glioma is the most common and aggressive human primary tumor in the central nervous system. Despite present clinical advancements, median survival time remains poor in this malignant tumor. Serpin peptidase inhibitor, clade A member 3 (SERPINA3), is a member of the serpin superfamily of protease inhibitors. Its aberra...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S133022
更新日期:2017-04-18 00:00:00
abstract::Prostate cancer is the leading malignancy and the second most common cause of cancer-related death in men. Despite high cure rates with surgery and/or radiation, 30%-40% of patients eventually develop advanced cancer. Docetaxel is one of the most effective and well established chemotherapeutic agents for prostate canc...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S79105
更新日期:2015-04-10 00:00:00
abstract::Mesothelin (MSLN) is considered a promising target for cancer therapy. Originally extracted in 1992 after the immunization of mice with a human ovarian cancer (OC) cell line and cloned in 1996, MSLN seems to be involved in cell adhesion and metastasis. MSLN is prevalent in mesothelia tissues but is expressed in severa...
journal_title:OncoTargets and therapy
pub_type: 杂志文章,评审
doi:10.2147/OTT.S145105
更新日期:2017-11-08 00:00:00
abstract::Background: CD19-directed chimeric antigen receptor (CAR) T cells have substantial benefit in the treatment of patients with B-cell malignancies. However, despite encouraging therapeutic efficiency, there is limited overall response rate when anti-CD19 CAR-T cells are used to treat patients with relapsed and refractor...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S198567
更新日期:2019-07-12 00:00:00
abstract:INTRODUCTION:The purpose of this study was to evaluate the use of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography ((18)F-FDG PET/CT) to identify the presence of cervical lymph nodes metastases and extracapsular spread with histologic correlations in head and neck squamous cell carcinoma. METH...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S85479
更新日期:2015-08-26 00:00:00
abstract:Background:Insulin-like growth factor binding protein-2 (IGFBP2) levels are significantly increased in the plasma of hepatocellular carcinoma (HCC) patients. However, the correlation between IGFBP2 levels and clinical parameters and the exact role of IGFBP2 in HCC are unclear. In this study, we identified the role and ...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S249527
更新日期:2020-06-08 00:00:00
abstract:Introduction:The purpose of present study was to investigate the effect of limonin on tumor glycolysis and the underlying mechanisms in hepatocellular carcinoma (HCC). Methods:Cell proliferation and colony formation assays were performed to evaluate the potency of limonin against HCC cells in vitro. The glucose consum...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S165220
更新日期:2018-07-03 00:00:00
abstract:BACKGROUND:Chemotherapy is not limited to a single treatment, and the evidence demonstrates that different drug combinations can have positive results in patients. In this study, we sought to determine whether cordycepin combined with cisplatin and/or paclitaxel would have an additive effective on inducing apoptosis in...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S87010
更新日期:2015-09-01 00:00:00
abstract:Background:The mortality rate associated with ovarian cancer ranks the highest among gynecological malignancies. However, the cause and underlying molecular events of ovarian cancer are not clear. Here, we applied integrated bioinformatics to identify key pathogenic genes involved in ovarian cancer and reveal potential...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S152238
更新日期:2018-03-15 00:00:00
abstract::Large granular lymphocytic leukemia (LGLL) is a rare lymphoproliferative disorder of transformed natural killer or T-cells attributed to chronic exposure to the proinflammatory cytokine IL-15. Diagnosis of the majority of T-cell LGLL is established by documenting clonal large granular lymphocytes (LGLs) in peripheral ...
journal_title:OncoTargets and therapy
pub_type:
doi:10.2147/OTT.S115892
更新日期:2016-12-19 00:00:00
abstract::Lung cancer has the highest morbidity and mortality in the world, and non-small cell lung carcinomas (NSCLC) account for 80% of cases of lung cancer. The mechanism of NSCLC is still largely unknown, and finding novel targets is of great importance for the treatment of NSCLC. The current study was designed to evaluate ...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S123518
更新日期:2017-03-02 00:00:00
abstract:Background:This study investigated the effect of hyaluronic acid (HA)-CD44st on the invasive ability of human breast cancer MCF-7 cells and the correlation between the expression of CD44st and human epidermal growth factor receptor-2 (HER-2) in postoperative breast cancer patients. Materials and methods:MCF-7 cells tr...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S160531
更新日期:2018-09-10 00:00:00
abstract::[This corrects the article DOI: 10.2147/OTT.S227758.]. ...
journal_title:OncoTargets and therapy
pub_type: 已发布勘误
doi:10.2147/OTT.S242712
更新日期:2020-01-29 00:00:00
abstract::EGFR pathway is an important therapeutic target in human tumors, including metastatic colorectal cancer (mCRC). The advent of EGFR-targeted monoclonal antibodies panitumumab and cetuximab has generated promise for the treatment of mCRC and has largely improved patients' progression-free survival (PFS) and overall surv...
journal_title:OncoTargets and therapy
pub_type: 杂志文章,评审
doi:10.2147/OTT.S86966
更新日期:2016-01-27 00:00:00
abstract::[This corrects the article on p. 5203 in vol. 9, PMID: 27578986.]. ...
journal_title:OncoTargets and therapy
pub_type: 已发布勘误
doi:10.2147/OTT.S139588
更新日期:2017-04-27 00:00:00
abstract:Introduction:Esophageal squamous cell carcinoma (ESCC) is a malignant tumor disease with high mortality and morbidity rates, especially for a terminal cancer. At present, the prognosis and treatment of ESCC cannot effectively control or inhibit the spread and proliferation of tumor cells. microRNAs, a class of small sp...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S248925
更新日期:2020-08-13 00:00:00
abstract::Recent studies have shown that microRNAs play a pivotal role in the pathogenesis of cancer. In our current study, the expression levels of microRNA-211 (miR-211) were measured in human non-small-cell lung cancer (NSCLC) tissues and cell lines. We found that miR-211 expression levels were increased in NSCLC tissues and...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S143084
更新日期:2017-11-28 00:00:00
abstract::MicroRNAs (miRs) have been demonstrated to play key roles in the development and progression of hepatocellular carcinoma (HCC). However, the regulatory mechanism of miR-503 in HCC has not been fully uncovered. In this study, we found that miR-503 was significantly downregulated in HCC tissues compared to nontumorous l...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S106351
更新日期:2016-06-15 00:00:00